Elite Pharmaceuticals (ELTP) 10-Q2008 Q3 Quarterly report

Filed: 14 Feb 08, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: anintegral, announced, Apfel, ascribed, Assessment, assuming, assumption, back, case, ceased, condensed, curtail, customary, declined, deconsolidated, developmental, director, divested, doubt, euphoria, evidence, fluctuate, forfeited, hand, hereunder, inception, independent, insufficient, inventory, issuable, level, negotiated, ninety, notified, pharmacokinetic, proportionate, protocol, pursue, reach, reached, recently, recreational, rely, removal, representation, safety, seasonality, shipped, significantly, SPA, sponsored, Stuart, submitted, Theaccompanying, transportation, undertaken, valuation, verifying, wait

Removed: achievement, achieving, affiliate, aforementioned, amendment, application, approval, approved, attainment, authorize, automobile, average, bear, Behl, Berk, Bernard, budget, Canada, Chairman, collaboration, commencement, Committee, Comprehensive, consecutive, consummation, Cosmetic, coverage, designated, designee, Dick, discussed, employee, entertainment, equally, equivalent, European, extended, faith, Federal, financed, formulated, Head, health, implementing, Indigo, insurance, intellectual, intent, IPC, Japan, law, mental, occurred, party, perform, permanent, person, physical, pliva, power, President, profit, PTO, receive, Reconciliation, reduction, reference, reimbursable, reimbursement, released, rendered, restated, scientific, sell, senior, seq, shared, sharing, single, subscribed, subsequently, Technical, thereof, TPN, trading, tranche, travel, Union, unpaid, utilization, Vice, waived, welfare, work

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

ELTP similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Elite Pharmaceuticals, Inc. (the “Company”) on Form 10-Q for the quarter ended December 31, 2007 filed with the Securities and Exchange Commission (the “Report”), I, Mark I. Gittelman, Chief Financial Officer and Treasurer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

	(1)	The Report fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934; and

	(2)	The information contained in the Report fairly presents, in all material respects, the consolidated financial condition of the Company as of the dates presented and the consolidated result of operations of the Company for the periods presented.

		/s/ Mark I. Gittelman
Date:	February 14, 2008
		Mark I. Gittelman
		Chief Financial Officer and Treasurer of
		Elite Pharmaceuticals, Inc.

This certification has been furnished solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

A signed original of this written statement required by Section 906 has been provided to Elite Pharmaceuticals, Inc. and will be retained by Elite Pharmaceuticals, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.